Two monoclonal IgG3 (kappa) antibodies against murine Thy-1.2 antigen produced by murine 1B5 and 1aG4/C5 hybridomas were partially characterized. The 1aG4/C5 antibody has slightly higher affinity for the Thy-1.2 antigen in binding tests and more efficiently kills the Thy-1.2+ thymocytes in cytotoxicity assays as compared to the 1B5 antibody. The latter, in addition, reacts significantly with the Thy-1.1 antigen (the allelic form of Thy-1 antigen expressed on the cells of the donor of the immune cells. Both monoclonal antibodies exhibit some characteristic properties of IgG3 of myeloma origin, e.g. a tendency to aggregation, high pI and interaction with protein A. Our monoclonal antibodies are sensitive to pepsin digestion, resistant to trypsin, their disulphide bonds are rapidly cleaved by sulphitolysis and reduction by dithiothreitol. They possess characteristic acidic peptides bearing the disulphide bonds between the heavy chains. These antibodies, however, differ to some extent from each other in some properties (precipitation with staphylococcal protein A, solubility, pI, electrophoretic behaviour of the light chains). They possess different heavy chain peptides bearing the interchain disulphide bonds and thus they probably differ in the hinge region. This structural difference may be associated with different sensitivity of these two antibodies to sulphitolysis and proteolysis.
Download full-text PDF |
Source |
---|
Sci Rep
January 2025
Center of Excellence for Antimicrobial Resistance and Stewardship, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.
The pathogenic oomycete Pythium insidiosum causes a fatal infectious illness known as pythiosis, impacting humans and certain animals in numerous countries in the tropics and subtropics. Delayed diagnosis is a primary factor contributing to the heightened morbidity and mortality associated with the disease. Several new serodiagnostic methods have been developed to improve the identification of pythiosis.
View Article and Find Full Text PDFActa Parasitol
January 2025
World Health Organization Regional Office for Southeast Asia, New Delhi, India.
Purpose: A comprehensive survey was conducted to assess the prevalence of Schistosoma japonicum infection in humans, water buffaloes, and snails in the two endemic municipalities of Talibon and Trinidad in Bohol, Philippines, which are nearing elimination.
Methods And Results: Human stool and blood samples were collected from barangays with snail breeding sites, and results showed higher positivity rates using the rSjTPx-1-ELISA compared to the Kato-Katz technique. Human stool examination for showed a 0.
NPJ Prim Care Respir Med
January 2025
Université Paris Cité, Department of general practice, Paris, France, Paris, France.
Streptococcus pneumoniae (SP) remains an important cause of community acquired pneumonia (CAP). We aimed to describe the prevalence and characteristics of outpatients with radiologically confirmed pneumococcal CAP. Between November 2017 and December 2019, a French network of general practitioners enrolled CAP-suspected adults, with ≥1 clinical signs of infection and ≥1 signs of pulmonary localization in an observational study.
View Article and Find Full Text PDFVet Res
January 2025
College of Veterinary Medicine, Jeonbuk National University, Iksan Campus, Iksan, 54596, Republic of Korea.
Fowl typhoid (FT) poses a significant threat to the poultry industry and can cause substantial economic losses, especially in developing regions. Caused by Salmonella Gallinarum (SG), vaccination can prevent FT. However, existing vaccines, like the SG9R strain, have limitations, including residual virulence and potential reversion of pathogenicity.
View Article and Find Full Text PDFJ Transl Med
January 2025
Evvivax Biotech, Via Castel Romano 100, 00128, Rome, Italy.
In the past decades, Chimeric Antigen Receptor (CAR)-T cell therapy has achieved remarkable success, leading to the approval of six therapeutic products for haematological malignancies. Recently, the therapeutic potential of this therapy has also been demonstrated in non-tumoral diseases. Currently, the manufacturing process to produce clinical-grade CAR-T cells is complex, time-consuming, and highly expensive.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!